DKK1 and sclerostin are early markers of relapse in multiple myeloma.
Bone
; 113: 114-117, 2018 08.
Article
em En
| MEDLINE
| ID: mdl-28993177
ABSTRACT
Recent studies have shown that Dickkopf-related protein (DKK1) and sclerostin decrease when a complete response (CR) is obtained after chemotherapy in myeloma multiple (MM). To study variations in DKK1, sclerostin and P1NP in patients treated for MM, between complete response (CR) and relapse, we carried out a prospective study ancillary to the IFM 2009 protocol (IFM). The aim of IFM was to compare progression-free survival between patients treated with chemotherapy with or without transplantation. We selected 69 patients who reached CR and relapsed. We assayed by ELISA DKK1, sclerostin and P1NP at 3 end points T1 CR, T2 4â¯months before relapse and T3 relapse. There was a significant increase in DKK1 and sclerostin between T1, T2 and T3. (DKK1 medians (IQR) T1â¯=â¯30â¯pmol/l (20.4-41.1), T2â¯=â¯37.4â¯pmol/l (29.8-49.4), pâ¯<â¯0.0001, T3â¯=â¯42â¯pmol/l (33.8-55.5), pâ¯<â¯0.0001 sclerostin medians (IQR) T1â¯=â¯0.57 (0.47-0.69), T2â¯=â¯0.62â¯ng/ml (0.53-0.79), pâ¯<â¯0.0001, T3â¯=â¯n0.64â¯ng/ml (0.56-0.79), pâ¯=â¯0.005). No significant variation was detected in the levels of P1NP. No association was observed between the characteristics of the MM, or the treatment received and the variation between T1-T3 for DKK1, sclerostin or P1NP. A significant increase in DKK1 and sclerostin was observed four months before relapse.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Biomarcadores Tumorais
/
Proteínas Morfogenéticas Ósseas
/
Peptídeos e Proteínas de Sinalização Intercelular
/
Mieloma Múltiplo
Tipo de estudo:
Clinical_trials
/
Guideline
/
Observational_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article